If the presence of the CD56dim CD16low cells in NB patients at early phase post-transplant will be confirmed, this population could be activated, for example, by multifunctional engagers targeting NKp46 on NK cells [113] and a tumor antigen on NB cells, contributing to the control of BM residual disease. This evidence concerns the gene NCR1 and neuroblastoma.